Palcebo

DRUG6 trials

Conditions

HealthyOverweight and Obese VolunteersProstate CancerTreatment of Excessive Daytime Sleepiness in NarcolepsyType 2 Diabetesnon alcohlic fatty liver disease. Other diseases of liver

Phase 1

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

CompletedNCT04250363

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyHealthy

Start: 2020-02-17End: 2021-08-18Updated: 2024-05-01

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

RecruitingNCT06778850

MindRank AI LtdOverweight and Obese Volunteers

Start: 2023-06-09End: 2025-12-30Target: 131Updated: 2025-03-07

Phase 2

A Study of HS-20094 in Patients With T2DM

CompletedNCT06901648

Jiangsu Hansoh Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2024-02-06End: 2025-04-09Updated: 2025-08-01

Phase 3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

TerminatedNCT00626548

AstraZenecaProstate Cancer

Start: 2008-01-31End: 2011-05-31Updated: 2012-09-03

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

CompletedNCT01638403

BioprojetTreatment of Excessive Daytime Sleepiness in Narcolepsy

Start: 2010-11-30End: 2012-07-31Updated: 2017-01-31

Unknown Phase

Effect of vitamin D supplementation on inflammatory markers, liver function, lipid profile, body composition, and sonographic findings in patients with NAFLD

Active, not recruitingIRCT2013060411763N8

Food Security Research Centernon alcohlic fatty liver disease. Other diseases of liver

Start: 2012-06-20Target: 60Updated: 2018-02-22

Journal of Clinical Oncology2024-05-292 citations

Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.

2023-07-0316 citations

Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials

BMC Psychiatry2022-02-229 citations

External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-05-20

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

2012-05-1233 citations